Clinical Trial Search

Primary: Mean Change From Baseline in Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) at Day 8 — -1.06; 0.10 Log 10 copies per milliliter (c/mL)…

Primary: Occurrence of Related Adverse Events - Grade 3 or Higher — 0; 0; 0 participants

Primary: Forced Vital Capacity (FVC) at Baseline and End of Period 1 — 2.74; 2.83; 2.40; 2.57 litres — p=0.9631

Primary: Objective CPAP Use — 0.437; -0.066 log(hours/night)

Primary: Fugl-Meyer Score Change Immediately Following Study Intervention. — 6.8; 14.4; 14.0 units on a scale

Primary: Glucagon Response to Acute Hypoglycaemia — 1.33; 1.0; 1.33 pmol/L — p=1.0

Primary: In Vivo Linear Knee Kinematics From Fluoroscopy Evaluation During Deep Knee Bend Activity — -4.1; 1.2 mm

Primary: Percentages of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV — 46; 89; 43; 90…

Primary: Change in Body Weight — -5.6; -3.1 kg

Primary: Maximum Observed Plasma Concentration (Cmax): Day 1 — 3467.0; 27437.1; 23046.7; 48392.6 nanogram per milliliter (ng/mL)

Primary: Beck Depression Inventory - II — 25.47; 27.13; 18.84; 25.00 units on a scale

Primary: Number of Participants With Clinical Response at Week 6 — 76; 129; 141 Participants — p=<0.0001

Primary: Number of Participants With Any On-treatment Adverse Event (AE) or Any On-treatment Serious Adverse Event (SAE) — 6; 2; 8; 5 participants

Primary: Change From Baseline and Levels at Each Time Point for Serum Phosphorus — -0.2; -0.1; -0.2; 0.1 mg/dL

Primary: Percentage of Participants Achieving SVR12 — 78; 0 percentage of participants — p=< 0.001